Wefel Jeffrey S, Noll Kyle R, Scheurer Michael E
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lancet Oncol. 2016 Mar;17(3):e97-e108. doi: 10.1016/S1470-2045(15)00380-0. Epub 2016 Mar 2.
Impairment of neurocognitive functioning is a common result of cerebral neoplasms and treatment, although there is substantial heterogeneity in the pattern and severity of neurocognitive dysfunction across individuals and tumour types. The effects of many clinical and patient characteristics on neurocognitive functioning have been documented, but little research has been devoted to understanding the effect of genetic variation on neurocognitive outcomes in patients with brain tumours. This Review highlights preliminary evidence that suggests an association between various genes and risk of adverse neurocognitive outcomes in patients with brain tumours. Studies include genes specific to neuronal function, and those associated with more systemic cellular regulation. Related scientific literature in other disease populations is briefly discussed to indicate additional candidate genes. We consider methodological issues central to the study of neurocognitive functioning and genetic associations for patients with brain tumours, and emphasise the need for future research integrating novel investigative techniques.
神经认知功能受损是脑肿瘤及其治疗的常见结果，尽管个体和肿瘤类型之间神经认知功能障碍的模式和严重程度存在很大差异。许多临床和患者特征对神经认知功能的影响已有文献记载，但很少有研究致力于了解基因变异对脑肿瘤患者神经认知结果的影响。本综述强调了初步证据，表明各种基因与脑肿瘤患者不良神经认知结果的风险之间存在关联。研究包括神经元功能特异性基因以及与更全面的细胞调节相关的基因。还简要讨论了其他疾病人群中的相关科学文献，以指出其他候选基因。我们考虑了脑肿瘤患者神经认知功能和基因关联研究的核心方法学问题，并强调未来整合新型研究技术的研究的必要性。
